Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG2035

CEP68 Knockout Raji Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Bone

  • Disease:

    Burkitt lymphoma

The CEP68 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the centrosomal scaffold protein CEP68 in the Raji B-lymphoblast line. CEP68 maintains centriole cohesion through interactions with CEP250, rootletin, and other centrosomal components, and its activity is regulated by mitotic kinases PLK1 and Aurora A. Loss of function leads to premature centriole separation, mitotic defects, and aneuploidy, mimicking centrosome-related genomic instability. This model supports centrosome biology, cancer cell studies, and drug screening, employing immunofluorescence, live-cell imaging, flow cytometry, and aneuploidy assays. For lymphoma and centrosome research, it offers a genetically defined system.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    Raji

    Cell Type

    B cell line

    Sex of Donor

    Male

    Age

    11 years

    Derived From Site

    In situ; Maxilla

    Gene Name

    CEP68

    Gene Identifier

    NCBI Gene ID 23177

    Morphology

    Lymphoblast-like

    Growth Mode

    Suspension

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    RPMI 1640

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The CEP68 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population, created by targeted disruption of the CEP68 gene in the Raji human B-lymphoblast line. This product offers a genetically defined loss-of-function model for mechanistic studies in centrosome biology, mitotic regulation, and cancer research. The polyclonal format maintains a heterogeneous pool of edited alleles, capturing the collective phenotypic consequences of CEP68 loss and providing population-level robustness suitable for pooled screens, dose-response testing, and assays where clonal uniformity is not desired.

Raji cells originate from an EBV-positive Burkitt??s lymphoma and grow as a suspension lymphoblastoid line, retaining mature B-lymphocyte features such as surface immunoglobulin expression and MHC class II-mediated antigen presentation. They are a cornerstone model for B-cell lymphoma due to their rapid doubling time, sustained proliferative capacity, and karyotypic abnormalities that mirror chromosomal instability seen in aggressive disease. The endogenous EBV latency program interferes with host DNA damage checkpoints, creating a permissive environment in which centrosomal perturbations may unmask synthetic lethal interactions or amplify aneuploidy.

CEP68 is a key centrosomal scaffold that enforces centriole cohesion during interphase. It localizes to the proximal ends of centrioles, bridging mother and daughter centrioles through interactions with CEP250 (C-Nap1) and rootletin. This tethering is dynamically dismantled by mitotic kinases PLK1, Aurora A, and CDK1 to permit centrosome separation. Additional partners CEP63, CEP152, and CPAP integrate CEP68 into centriole duplication and microtubule organization. Disruption abolishes this regulation, causing premature centriole splitting, centrosome fragmentation, and mitotic spindle defects. The resulting chromosome missegregation promotes aneuploidy, a hallmark of aggressive cancers. Ciliogenesis may also be impaired in non-cycling cells.

Within the Raji lymphoma model, CEP68 knockout amplifies the cell line??s intrinsic genomic instability. Raji cells frequently harbor supernumerary centrosomes, and the additional loss of cohesion is expected to trigger multipolar mitoses, transient spindle pole clustering errors, and catastrophic chromosome segregation, accelerating aneuploidy generation. This establishes a powerful system to explore how centrosome dysfunction contributes to lymphomagenesis and to uncover cancer cell?Cspecific dependencies. The suspension culture format enables large-scale live-cell imaging of mitotic progression, flow cytometric cell cycle analysis, and immunofluorescence-based quantification of centrosome numbers, directly linking molecular lesions to cellular outcomes.

Researchers can employ this CEP68 knockout population in diverse experimental workflows. Standard assays include immunofluorescence staining for gamma-tubulin or centrin to assess centrosome integrity, western blotting for CEP68 depletion, and flow cytometry for DNA content and proliferation. Live-cell imaging with fluorescent reporters for tubulin and kinetochores captures dynamic spindle defects. The model is amenable to high-throughput phenotypic screening for compounds that restore cohesion or exploit aneuploidy. For technical support or custom product information, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)